Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Debt to Equity (2021 - 2024)

Inmune Bio's Debt to Equity history spans 4 years, with the latest figure at $0.13 for Q3 2024.

  • For Q3 2024, Debt to Equity fell 54.16% year-over-year to $0.13; the TTM value through Sep 2024 reached $0.13, down 54.16%, while the annual FY2023 figure was $0.27, 8.66% up from the prior year.
  • Debt to Equity for Q3 2024 was $0.13 at Inmune Bio, down from $0.28 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.53 in Q1 2024 and bottomed at $0.1 in Q2 2023.
  • The 4-year median for Debt to Equity is $0.24 (2022), against an average of $0.24.
  • The largest annual shift saw Debt to Equity plummeted 54.31% in 2023 before it soared 188.93% in 2024.
  • A 4-year view of Debt to Equity shows it stood at $0.18 in 2021, then skyrocketed by 35.68% to $0.24 in 2022, then increased by 8.66% to $0.27 in 2023, then crashed by 51.4% to $0.13 in 2024.
  • Per Business Quant, the three most recent readings for INMB's Debt to Equity are $0.13 (Q3 2024), $0.28 (Q2 2024), and $0.53 (Q1 2024).